Related Experiment Video
Updated: Aug 31, 2025
Early Pathological and Magnetic Resonance Detection of Cerebral Injury Using a Rat Model of Neonatal Hypoxic Ischemic Encephalopathy
Published on: October 28, 2022
Protecting against brain damage by improving treatment in neonates with hypoglycaemia: ProBrain-D-a study protocol of
Henrike Hoermann1, Marcia Roeper1, Roschan Salimi Dafsari1
1Department of General Paediatrics, Neonatology and Paediatric Cardiology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany.
Insights
This study introduces a new standard for diagnosing and treating neonatal hypoglycemia, aiming to improve neurodevelopmental outcomes in at-risk infants. It also assesses the standard's feasibility and acceptance among healthcare professionals and parents.
Area of Science:
- Neonatal Medicine
- Developmental Pediatrics
- Metabolic Disorders
Background:
- Neonatal hypoglycemia is common, yet lacks standard screening and treatment guidelines.
- Controversies exist regarding glucose administration thresholds and the effects of mild hypoglycemia on neurodevelopment.
- Severe hypoglycemia can cause brain damage, but mild cases' long-term neurological impact is under-researched.
Purpose of the Study:
- To evaluate if a new diagnostic and treatment standard improves neurodevelopmental outcomes in neonates at risk for hypoglycemia.
- To assess the acceptance and feasibility of the new standard among healthcare professionals and parents.
- To establish a benchmark for neonatal hypoglycemia management and its impact on infant development.
Main Methods:
- A monocentric prospective cohort study involving 678 neonates (≥35 weeks gestation) after implementing a new standard operating procedure (SOP).
- A retrospective cohort of 139 neonates born before SOP implementation for comparison.
- Neurological outcomes assessed using Bayley Scales of Infant Development at 2-2.5 years; clinical data and developmental milestones tracked up to 24 months.
Main Results:
- Comparative analyses of neurological outcomes between prospective and retrospective cohorts are planned.
- Longitudinal data collection on clinical course, nutrition, and developmental milestones will provide comprehensive insights.
- Questionnaires will measure the acceptance and feasibility of the new standard.
Conclusions:
- The study aims to provide evidence-based recommendations for neonatal hypoglycemia management.
- Findings will inform the development of standardized guidelines for screening and treatment.
- This research seeks to optimize care for at-risk neonates and enhance long-term neurodevelopmental health.
Introduction:
Although neonatal hypoglycaemia is the most common metabolic problem in neonates, there is no standard guideline for screening. Additionally, treatment of neonatal hypoglycaemia and glucose administration thresholds are discussed controversially. Severe hypoglycaemia can lead to brain damage, but data on the effects of mild hypoglycaemia on neurological development are limited. To our knowledge, this is the first prospective longitudinal cohort study to analyse if the implementation of a new diagnosis and treatment standard for neonatal hypoglycaemia may improve the outcome of neonates at risk for hypoglycaemia, especially concerning neurodevelopment. Furthermore, the acceptance and feasibility of the standard among different professional groups and parents are analysed.
Methods And Analysis:
After implementation of a structured standard operating procedure (SOP), detailing preventive measures, blood glucose screening and neonatal hypoglycaemia treatment in a tertiary care hospital, 678 neonates ≥35+0 weeks of gestation will be recruited in a monocentric prospective cohort study. For comparison, 139 children born before the implementation of this new SOP, who had risk factors for neonatal hypoglycaemia or qualified for blood glucose measurements are recruited (retrospective cohort). For the primary end point, comparative analyses between and within the prospective and retrospective cohorts will be performed regarding the neurological outcome at 2-2.5 years of age in Bayley Scales of Infant Development. Furthermore, comprehensive clinical data and data on nutrition and developmental milestones are assessed at different time points (6 weeks, 6, 12, 18 and 24 months) in the prospective cohort. Acceptance and feasibility of the new standard are assessed using questionnaires.
Ethics And Dissemination:
The study has been approved by the Ethics Committee of the Medical Faculty of the Heinrich-Heine-University Düsseldorf (20201162). The results of this study will be disseminated through peer-reviewed journals and presented at international conferences.
Trial Registration Number:
DRKS00024086.
Related Concept Videos
01:15Hypoglycemia and Glucagon
00:49The Blood-brain Barrier